Immune checkpoint inhibitor-related adverse events: Real-world experience from a single veterans' affairs medical center.

Samantha BenzKatherine A ShermanConstantin A Dasanu Juliana Alvarez-Argote

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

Immune-related complications due to ICI therapy are common and can frequently lead to treatment discontinuation in the real-world setting. Endocrine and intestinal irAEs may correlate with improved survival. The ICI-treated patients who received palliative radiation therapy to the bone had less irAEs, possibly due to immunogenic cell death.

Keyphrases

radiation therapy
cell death
risk factors
palliative care
stem cells
bone mineral density
squamous cell carcinoma
body composition
radiation induced
signaling pathway
newly diagnosed
bone loss
pi k akt
cell cycle arrest